Palisade Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PALI research report →
About the company
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes.
- CEO
- J. D. Finley
- IPO
- 2007
- Employees
- 8
- HQ
- Carlsbad, CA, US
Price Chart
- Market Cap
- $364.52M
- P/E
- -1.98
- P/S
- 0.00
- P/B
- 3.46
- EV/EBITDA
- -9.12
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -36.79%
- ROIC
- -20.75%
- Revenue
- $0 · 0.00%
- Net Income
- $-16,781,000 · -16.23%
- EPS
- $-0.30 · 97.06%
- Op Income
- $-18,056,000
- FCF YoY
- 11.04%
- 52W High
- $2.86
- 52W Low
- $0.53
- 50D MA
- $1.93
- 200D MA
- $1.84
- Beta
- 1.51
- Avg Volume
- 3.82M
Get TickerSpark's AI analysis on PALI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 10, 26 | Baltera Robert Jr. | other | 336,904 |
| Jun 10, 26 | Baltera Robert Jr. | other | 0 |
| Jun 10, 26 | Wei Binxian | other | 20,200 |
| Jun 10, 26 | Wei Binxian | other | 592,300 |
| Jun 10, 26 | Wei Binxian | other | 20,200 |
| Jun 10, 26 | Williams Donald Allen | other | 60,666 |
| Jun 10, 26 | Williams Donald Allen | other | 1,498,900 |
| Jun 10, 26 | Williams Donald Allen | other | 60,666 |
| Jun 10, 26 | Chuang Emil | other | 20,200 |
| Jun 10, 26 | Chuang Emil | other | 592,300 |
Our PALI coverage
Recent articles, reports, and earnings notes.
No research on PALI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PALI report →Similar companies
Peers in the same neighborhood.